ProLynx technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs.
ProLynx develops advanced linker technologies and a facile with a transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates. The company's technology is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs.
ProLynx was founded in 2009 by Daniel V. Santi and Gary W. Ashley and is based in San Francisco, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 1, 2020 | Grant | $230K | 1 |
![]() |
— | Detail |
Nov 1, 2018 | Grant | $150K | 1 |
![]() |
— | Detail |
Nov 1, 2016 | Grant | $250K | 1 |
![]() |
— | Detail |
Jun 1, 2015 | Grant | $141.69K | 1 |
![]() |
— | Detail |
Nov 1, 2014 | Grant | $742.77K | 1 |
![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Grant |
![]() |
Yes | Grant |